{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T23:39:23Z","timestamp":1792366763520,"version":"4.4.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangdong Basic and Applied Basic Research Foundation","award":["2024A1515110272"],"award-info":[{"award-number":["2024A1515110272"]}]},{"name":"Guangdong Basic and Applied Basic Research Foundation","award":["2022A1515110197"],"award-info":[{"award-number":["2022A1515110197"]}]},{"name":"Guangdong Basic and Applied Basic Research Foundation","award":["2023B1515120085"],"award-info":[{"award-number":["2023B1515120085"]}]},{"name":"Shenzhen Science and Technology Program","award":["JCYJ20220530152008019"],"award-info":[{"award-number":["JCYJ20220530152008019"]}]},{"name":"Huizhou Science and Technology Program","award":["2024CZ010270"],"award-info":[{"award-number":["2024CZ010270"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-026-04426-9","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T08:35:34Z","timestamp":1784709334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ACSF2 Functions as a regulatory switch for PARP inhibitor sensitivity in platinum-sensitive and homologous recombination\u2013proficient high-grade serous ovarian cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Sijia","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhi","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaru","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianle","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyang","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqin","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"issue":"10177","key":"4426_CR1","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240\u201353.","journal-title":"Lancet"},{"key":"4426_CR2","doi-asserted-by":"crossref","unstructured":"Yang L, Xie HJ, Li YY, Wang X, Liu XX, Mai J. Molecular mechanisms of platinum\u2013based chemotherapy resistance in ovarian cancer (Review). Oncol Rep 2022, 47(4):82.","DOI":"10.3892\/or.2022.8293"},{"issue":"10","key":"4426_CR3","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","volume":"34","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2023","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, Ray-Coquard I, Tan DSP, Bellet E, Oaknin A, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(10):833\u201348.","journal-title":"Ann Oncol"},{"issue":"5","key":"4426_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","volume":"21","author":"PM Webb","year":"2024","unstructured":"Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024;21(5):389\u2013400.","journal-title":"Nat Rev Clin Oncol"},{"issue":"13","key":"4426_CR5","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.7150\/jca.47695","volume":"12","author":"S Liu","year":"2021","unstructured":"Liu S, Wu M, Wang F. Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer. J Cancer. 2021;12(13):3976\u201396.","journal-title":"J Cancer"},{"issue":"7","key":"4426_CR6","first-page":"584","volume":"45","author":"A Association BoOPoCP","year":"2023","unstructured":"Association BoOPoCP A, CoCPoOoCA A, CoCPoOoZA A, CoADoZP. Association CoZE-bP: [Chinese expert consensus on drug interaction management of poly ADP-ribose polymerase inhibitors]. Zhonghua Zhong Liu Za Zhi. 2023;45(7):584\u201393.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"4426_CR7","doi-asserted-by":"crossref","unstructured":"Ledermann JA, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, Gonz\u00e1lez-Martin A, Gourley C, Leary A, Lorusso D et al. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol 2024, 35(3):248\u2013266.","DOI":"10.1016\/j.annonc.2023.11.015"},{"issue":"5","key":"4426_CR8","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","volume":"20","author":"KN Moore","year":"2019","unstructured":"Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):636\u201348.","journal-title":"Lancet Oncol"},{"issue":"9","key":"4426_CR9","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1001\/jamaoncol.2023.2283","volume":"9","author":"N Li","year":"2023","unstructured":"Li N, Zhu J, Yin R, Wang J, Pan L, Kong B, Zheng H, Liu J, Wu X, Wang L, et al. Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2023;9(9):1230\u20137.","journal-title":"JAMA Oncol"},{"issue":"3","key":"4426_CR10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","volume":"41","author":"P DiSilvestro","year":"2023","unstructured":"DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, et al. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1\/GOG 3004 Trial. J Clin Oncol. 2023;41(3):609\u201317.","journal-title":"J Clin Oncol"},{"issue":"34","key":"4426_CR11","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1200\/JCO.22.01003","volume":"40","author":"BJ Monk","year":"2022","unstructured":"Monk BJ, Parkinson C, Lim MC, O\u2019Malley DM, Oaknin A, Wilson MK, Coleman RL, Lorusso D, Bessette P, Ghamande S, et al. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45). J Clin Oncol. 2022;40(34):3952\u201364.","journal-title":"J Clin Oncol"},{"key":"4426_CR12","doi-asserted-by":"publisher","first-page":"112908","DOI":"10.1016\/j.ejca.2023.04.024","volume":"189","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2023","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, Freyer G, Backes F, Heitz F, Redondo A, et al. Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur J Cancer. 2023;189:112908.","journal-title":"Eur J Cancer"},{"issue":"11","key":"4426_CR13","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","volume":"35","author":"BJ Monk","year":"2024","unstructured":"Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick CC, Lorusso D, Moore RG, Freyer G, et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial. Ann Oncol. 2024;35(11):981\u201392.","journal-title":"Ann Oncol"},{"issue":"12","key":"4426_CR14","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s11912-022-01337-6","volume":"24","author":"CR Washington","year":"2022","unstructured":"Washington CR, Moore KN. Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse. Curr Oncol Rep. 2022;24(12):1685\u201393.","journal-title":"Curr Oncol Rep"},{"key":"4426_CR15","doi-asserted-by":"publisher","first-page":"100744","DOI":"10.1016\/j.drup.2021.100744","volume":"55","author":"M Chiappa","year":"2021","unstructured":"Chiappa M, Guffanti F, Bertoni F, Colombo I, Damia G. Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer. Drug Resist Updat. 2021;55:100744.","journal-title":"Drug Resist Updat"},{"key":"4426_CR16","doi-asserted-by":"crossref","unstructured":"Cordani N, Bianchi T, Ammoni LC, Cortinovis DL, Cazzaniga ME, Lissoni AA, Landoni F, Canova S. An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective. Int J Mol Sci 2023, 24(15):11890.","DOI":"10.3390\/ijms241511890"},{"issue":"22","key":"4426_CR17","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1016\/j.molcel.2021.09.005","volume":"81","author":"M Paes Dias","year":"2021","unstructured":"Paes Dias M, Tripathi V, van der Heijden I, Cong K, Manolika EM, Bhin J, Gogola E, Galanos P, Annunziato S, Lieftink C, et al. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1\/53BP1 double-deficient cells by exposing ssDNA gaps. Mol Cell. 2021;81(22):4692\u2013e47084699.","journal-title":"Mol Cell"},{"issue":"19","key":"4426_CR18","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1038\/s41388-022-02299-6","volume":"41","author":"H Fujita","year":"2022","unstructured":"Fujita H, Ikeda M, Ui A, Ouchi Y, Mikami Y, Kanno SI, Yasui A, Tanaka K. CHAMP1-POGZ counteracts the inhibitory effect of 53BP1 on homologous recombination and affects PARP inhibitor resistance. Oncogene. 2022;41(19):2706\u201318.","journal-title":"Oncogene"},{"issue":"1","key":"4426_CR19","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.1038\/s41467-018-07855-x","volume":"9","author":"JR Becker","year":"2018","unstructured":"Becker JR, Cuella-Martin R, Barazas M, Liu R, Oliveira C, Oliver AW, Bilham K, Holt AB, Blackford AN, Heierhorst J, et al. The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity. Nat Commun. 2018;9(1):5406.","journal-title":"Nat Commun"},{"issue":"18","key":"4426_CR20","doi-asserted-by":"publisher","first-page":"12085","DOI":"10.1074\/jbc.M707974200","volume":"283","author":"H Yang","year":"2008","unstructured":"Yang H, Pesavento JJ, Starnes TW, Cryderman DE, Wallrath LL, Kelleher NL, Mizzen CA. Preferential dimethylation of histone H4 lysine 20 by Suv4-20. J Biol Chem. 2008;283(18):12085\u201392.","journal-title":"J Biol Chem"},{"issue":"11","key":"4426_CR21","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1002\/mc.23796","volume":"63","author":"P Yin","year":"2024","unstructured":"Yin P, Tang M, Zhao G. M2 macrophage exosome-derived Apoc1 promotes ferroptosis resistance in osteosarcoma by inhibiting ACSF2 deubiquitination. Mol Carcinog. 2024;63(11):2103\u201318.","journal-title":"Mol Carcinog"},{"key":"4426_CR22","doi-asserted-by":"publisher","first-page":"807862","DOI":"10.3389\/fcell.2021.807862","volume":"9","author":"H Wang","year":"2021","unstructured":"Wang H, Cheng Q, Chang K, Bao L, Yi X. Integrated Analysis of Ferroptosis-Related Biomarker Signatures to Improve the Diagnosis and Prognosis Prediction of Ovarian Cancer. Front Cell Dev Biol. 2021;9:807862.","journal-title":"Front Cell Dev Biol"},{"issue":"19","key":"4426_CR23","doi-asserted-by":"publisher","first-page":"7926","DOI":"10.18632\/aging.204323","volume":"14","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Liu M, Xu Z, Cai Y, Peng B, Liang Q, Yan Y, Liu W, Kang F, He Q, et al. Identification of ACSF gene family as therapeutic targets and immune-associated biomarkers in hepatocellular carcinoma. Aging. 2022;14(19):7926\u201340.","journal-title":"Aging"},{"issue":"1","key":"4426_CR24","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1186\/s12885-021-08341-2","volume":"21","author":"D Wang","year":"2021","unstructured":"Wang D, Wei G, Ma J, Cheng S, Jia L, Song X, Zhang M, Ju M, Wang L, Zhao L, et al. Identification of the prognostic value of ferroptosis-related gene signature in breast cancer patients. BMC Cancer. 2021;21(1):645.","journal-title":"BMC Cancer"},{"issue":"4","key":"4426_CR25","doi-asserted-by":"publisher","first-page":"413","DOI":"10.4103\/1735-5362.378088","volume":"18","author":"E Parsazad","year":"2023","unstructured":"Parsazad E, Esrafili F, Yazdani B, Ghafarzadeh S, Razmavar N, Sirous H. Integrative bioinformatics analysis of ACS enzymes as candidate prognostic and diagnostic biomarkers in colon adenocarcinoma. Res Pharm Sci. 2023;18(4):413\u201329.","journal-title":"Res Pharm Sci"},{"issue":"1","key":"4426_CR26","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13046-016-0461-5","volume":"35","author":"Z Mei","year":"2016","unstructured":"Mei Z, Zhang X, Yi J, Huang J, He J, Tao Y. Sirtuins in metabolism, DNA repair and cancer. J Exp Clin Cancer Res. 2016;35(1):182.","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"4426_CR27","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1038\/s41594-023-01107-3","volume":"30","author":"J Zhang","year":"2023","unstructured":"Zhang J, Chen F, Tian Y, Xu W, Zhu Q, Li Z, Qiu L, Lu X, Peng B, Liu X, et al. PARylated PDHE1\u03b1 generates acetyl-CoA for local chromatin acetylation and DNA damage repair. Nat Struct Mol Biol. 2023;30(11):1719\u201334.","journal-title":"Nat Struct Mol Biol"},{"issue":"2","key":"4426_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.molcel.2017.07.006","volume":"67","author":"SJ Linder","year":"2017","unstructured":"Linder SJ, Mostoslavsky R. Put Your Mark Where Your Damage Is: Acetyl-CoA Production by ACLY Promotes DNA Repair. Mol Cell. 2017;67(2):165\u20137.","journal-title":"Mol Cell"},{"issue":"7","key":"4426_CR29","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41419-023-05968-w","volume":"14","author":"S Yang","year":"2023","unstructured":"Yang S, Hwang S, Kim B, Shin S, Kim M, Jeong SM. Fatty acid oxidation facilitates DNA double-strand break repair by promoting PARP1 acetylation. Cell Death Dis. 2023;14(7):435.","journal-title":"Cell Death Dis"},{"issue":"6","key":"4426_CR30","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/nprot.2007.202","volume":"2","author":"D Shechter","year":"2007","unstructured":"Shechter D, Dormann HL, Allis CD, Hake SB. Extraction, purification and analysis of histones. Nat Protoc. 2007;2(6):1445\u201357.","journal-title":"Nat Protoc"},{"issue":"11","key":"4426_CR31","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1021\/pr900777e","volume":"8","author":"MD Plazas-Mayorca","year":"2009","unstructured":"Plazas-Mayorca MD, Zee BM, Young NL, Fingerman IM, LeRoy G, Briggs SD, Garcia BA. One-pot shotgun quantitative mass spectrometry characterization of histones. J Proteome Res. 2009;8(11):5367\u201374.","journal-title":"J Proteome Res"},{"issue":"19","key":"4426_CR32","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1091\/mbc.e12-07-0529","volume":"24","author":"AG Evertts","year":"2013","unstructured":"Evertts AG, Manning AL, Wang X, Dyson NJ, Garcia BA, Coller HA. H4K20 methylation regulates quiescence and chromatin compaction. Mol Biol Cell. 2013;24(19):3025\u201337.","journal-title":"Mol Biol Cell"},{"key":"4426_CR33","doi-asserted-by":"publisher","first-page":"101077","DOI":"10.1016\/j.drup.2024.101077","volume":"74","author":"F Wang","year":"2024","unstructured":"Wang F, Yu X, Qian J, Cao Y, Dong S, Zhan S, Lu Z, Bast RC Jr., Song Q, Chen Y, et al. A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer. Drug Resist Updat. 2024;74:101077.","journal-title":"Drug Resist Updat"},{"issue":"9","key":"4426_CR34","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1158\/1541-7786.MCR-17-0688","volume":"16","author":"KL Paquin","year":"2018","unstructured":"Paquin KL, Howlett NG. Understanding the Histone DNA Repair Code: H4K20me2 Makes Its Mark. Mol Cancer Res. 2018;16(9):1335\u201345.","journal-title":"Mol Cancer Res"},{"issue":"9","key":"4426_CR35","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.celrep.2017.05.016","volume":"19","author":"S Pellegrino","year":"2017","unstructured":"Pellegrino S, Michelena J, Teloni F, Imhof R, Altmeyer M. Replication-Coupled Dilution of H4K20me2 Guides 53BP1 to Pre-replicative Chromatin. Cell Rep. 2017;19(9):1819\u201331.","journal-title":"Cell Rep"},{"issue":"8","key":"4426_CR36","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1158\/0008-5472.CAN-23-0628","volume":"83","author":"J Murai","year":"2023","unstructured":"Murai J, Pommier Y. BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality. Cancer Res. 2023;83(8):1173\u20134.","journal-title":"Cancer Res"},{"issue":"1","key":"4426_CR37","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41392-023-01548-8","volume":"8","author":"Q Li","year":"2023","unstructured":"Li Q, Qian W, Zhang Y, Hu L, Chen S, Xia Y. A new wave of innovations within the DNA damage response. Signal Transduct Target Ther. 2023;8(1):338.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"4426_CR38","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nrc3537","volume":"13","author":"SF Bunting","year":"2013","unstructured":"Bunting SF, Nussenzweig A. End-joining, translocations and cancer. Nat Rev Cancer. 2013;13(7):443\u201354.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"4426_CR39","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","volume":"18","author":"MP Dias","year":"2021","unstructured":"Dias MP, Moser SC, Ganesan S, Jonkers J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol. 2021;18(12):773\u201391.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"4426_CR40","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1038\/s41467-021-23463-8","volume":"12","author":"D Zatreanu","year":"2021","unstructured":"Zatreanu D, Robinson HMR, Alkhatib O, Boursier M, Finch H, Geo L, Grande D, Grinkevich V, Heald RA, Langdon S, et al. Pol\u03b8 inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. Nat Commun. 2021;12(1):3636.","journal-title":"Nat Commun"},{"issue":"1","key":"4426_CR41","doi-asserted-by":"publisher","first-page":"5822","DOI":"10.1038\/s41467-024-50158-7","volume":"15","author":"U Vekariya","year":"2024","unstructured":"Vekariya U, Minakhin L, Chandramouly G, Tyagi M, Kent T, Sullivan-Reed K, Atkins J, Ralph D, Nieborowska-Skorska M, Kukuyan AM, et al. PARG is essential for Pol\u03b8-mediated DNA end-joining by removing repressive poly-ADP-ribose marks. Nat Commun. 2024;15(1):5822.","journal-title":"Nat Commun"},{"issue":"1","key":"4426_CR42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1631\/jzus.B2000306","volume":"22","author":"F Zhang","year":"2021","unstructured":"Zhang F, Gong Z. Regulation of DNA double-strand break repair pathway choice: a new focus on 53BP1. J Zhejiang Univ Sci B. 2021;22(1):38\u201346.","journal-title":"J Zhejiang Univ Sci B"},{"issue":"1","key":"4426_CR43","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/s41467-022-28588-y","volume":"13","author":"S Feng","year":"2022","unstructured":"Feng S, Ma S, Li K, Gao S, Ning S, Shang J, Guo R, Chen Y, Blumenfeld B, Simon I, et al. RIF1-ASF1-mediated high-order chromatin structure safeguards genome integrity. Nat Commun. 2022;13(1):957.","journal-title":"Nat Commun"},{"issue":"3","key":"4426_CR44","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nchembio.2282","volume":"13","author":"KD Bromberg","year":"2017","unstructured":"Bromberg KD, Mitchell TR, Upadhyay AK, Jakob CG, Jhala MA, Comess KM, Lasko LM, Li C, Tuzon CT, Dai Y, et al. The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity. Nat Chem Biol. 2017;13(3):317\u201324.","journal-title":"Nat Chem Biol"},{"issue":"1","key":"4426_CR45","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/15384101.2017.1404210","volume":"17","author":"M Simonetta","year":"2018","unstructured":"Simonetta M, de Krijger I, Serrat J, Moatti N, Fortunato D, Hoekman L, Bleijerveld OB, Altelaar AFM, Jacobs JJL. H4K20me2 distinguishes pre-replicative from post-replicative chromatin to appropriately direct DNA repair pathway choice by 53BP1-RIF1-MAD2L2. Cell Cycle. 2018;17(1):124\u201336.","journal-title":"Cell Cycle"},{"key":"4426_CR46","doi-asserted-by":"crossref","unstructured":"Menendez-Montes I, Abdisalaam S, Xiao F, Lam NT, Mukherjee S, Szweda LI, Asaithamby A, Sadek HA. Mitochondrial fatty acid utilization increases chromatin oxidative stress in cardiomyocytes. Proc Natl Acad Sci U S A 2021, 118(34).","DOI":"10.1073\/pnas.2101674118"},{"issue":"2","key":"4426_CR47","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cell.2010.03.012","volume":"141","author":"SF Bunting","year":"2010","unstructured":"Bunting SF, Call\u00e9n E, Wong N, Chen HT, Polato F, Gunn A, Bothmer A, Feldhahn N, Fernandez-Capetillo O, Cao L, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell. 2010;141(2):243\u201354.","journal-title":"Cell"},{"issue":"36","key":"4426_CR48","doi-asserted-by":"publisher","first-page":"57679","DOI":"10.18632\/oncotarget.11023","volume":"7","author":"A Bakr","year":"2016","unstructured":"Bakr A, K\u00f6cher S, Volquardsen J, Petersen C, Borgmann K, Dikomey E, Rothkamm K, Mansour WY. Impaired 53BP1\/RIF1 DSB mediated end-protection stimulates CtIP-dependent end resection and switches the repair to PARP1-dependent end joining in G1. Oncotarget. 2016;7(36):57679\u201393.","journal-title":"Oncotarget"},{"issue":"1","key":"4426_CR49","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","volume":"18","author":"EM Swisher","year":"2017","unstructured":"Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O\u2019Malley DM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75\u201387.","journal-title":"Lancet Oncol"},{"issue":"22","key":"4426_CR50","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016;375(22):2154\u201364.","journal-title":"N Engl J Med"},{"issue":"7","key":"4426_CR51","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1158\/1541-7786.MCR-19-1057","volume":"18","author":"BT Sawyer","year":"2020","unstructured":"Sawyer BT, Qamar L, Yamamoto TM, McMellen A, Watson ZL, Richer JK, Behbakht K, Schlaepfer IR, Bitler BG. Targeting Fatty Acid Oxidation to Promote Anoikis and Inhibit Ovarian Cancer Progression. Mol Cancer Res. 2020;18(7):1088\u201398.","journal-title":"Mol Cancer Res"},{"issue":"21","key":"4426_CR52","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012;72(21):5588\u201399.","journal-title":"Cancer Res"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04426-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04426-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04426-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:42:00Z","timestamp":1792363320000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04426-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4426"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04426-9","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol for generating patient-derived ovarian cancer organoids from fresh clinical specimens was approved by the Ethics Committee of Huizhou Central People\u2019s Hospital (Huizhou, Guangdong Province, China). All enrolled patients provided written informed consent prior to participation.The experimental procedures involving female athymic nude mice (nu\/nu) were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Huizhou Central People\u2019s Hospital.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"341"}}